Abobotulinumtoxina injections in shoulder muscles to improve adult upper limb spasticity: Results from a phase 4 real-world study and a phase 3 open-label trial

J Rehabil Med. 2020 Jun 11;52(6):jrm00068. doi: 10.2340/16501977-2695.

Abstract

Botulinum toxins, such as abobotulinumtoxinA, are used to treat spasticity (muscle overactivity) in arm muscles. Spasticity in shoulder muscles occurs in many patients following a stroke. Shoulder spasticity can be painful and limit limb movement. This paper compares the results from patients who did and those who did not receive abobotulinumtoxinA injections in shoulder muscles (among other arm muscles) in 2 studies. In both studies, the results showed that more patients receiving treatment in shoulder muscles chose pain as a key goal for treatment and had reduced pain following treatment compared with patients not treated in the shoulder. In addition, patients receiving shoulder injections showed further improvement in arm movement compared with those not receiving shoulder injections. Overall, these results suggest that abobotulinumtoxinA treatment in shoulder muscles may improve outcomes for patients with arm spasticity involving the shoulder.

Keywords: abobotulinumtoxinA; botulinum toxins, type A; clinical trials, phase III; muscle spasticity; observational study; shoulder joint; shoulder pain.

Publication types

  • Clinical Trial, Phase III
  • Clinical Trial, Phase IV

MeSH terms

  • Acetylcholine Release Inhibitors / pharmacology
  • Acetylcholine Release Inhibitors / therapeutic use*
  • Adult
  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Humans
  • Injections
  • Male
  • Middle Aged
  • Muscle Spasticity / drug therapy*
  • Neuromuscular Agents / pharmacology
  • Neuromuscular Agents / therapeutic use*
  • Shoulder / abnormalities*
  • Treatment Outcome

Substances

  • Acetylcholine Release Inhibitors
  • Neuromuscular Agents
  • Botulinum Toxins, Type A
  • abobotulinumtoxinA